List of Viltepso drug patents

Viltepso is owned by Nippon Shinyaku.

Viltepso contains Viltolarsen.

Viltepso has a total of 2 drug patents out of which 0 drug patents have expired.

Viltepso was authorised for market use on 12 August, 2020.

Viltepso is available in solution;intravenous dosage forms.

Viltepso can be used as treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping.

Drug patent challenges can be filed against Viltepso from August, 2024.

The generics of Viltepso are possible to be released after 31 August, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10870676 NIPPON SHINYAKU Antisense nucleic acids
Aug, 2031

(8 years from now)

US9079934 NIPPON SHINYAKU Antisense nucleic acids
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 12, 2025
Orphan Drug Exclusivity (ODE) Aug 12, 2027

Drugs and Companies using VILTOLARSEN ingredient

NCE-1 date: August, 2024

Market Authorisation Date: 12 August, 2020

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in